Last updated July 18, 2026
Key finding
More participants in the CSII + Met + Pio group (78.7%, 59/75) achieved HbA1c < 6.5% compared with the CSII group (59.0%, 46/78; adjusted p < 0.05).
This study evaluated the effects of combining oral hypoglycemic agents with short-term intensive insulin therapy in newly diagnosed type 2 diabetes patients, finding improved glycemic outcomes with combination treatments.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of combining oral hypoglycemic agents with short-term intensive insulin therapy in newly diagnosed type 2 diabetes patients, finding improved glycemic outcomes with combination treatments.
These findings are significant as they suggest that combining oral medications with insulin therapy can enhance glycemic control in newly diagnosed type 2 diabetes patients. This approach may lead to better long-term outcomes and reduce the burden of insulin therapy, ultimately improving patient quality of life.
The study's findings may not be generalizable to all populations with type 2 diabetes. Sample sizes for each group may limit the robustness of the results. The duration of follow-up was limited to 12 months, which may not capture long-term effects.
Published in
Publication details and source links for this paper.
Weijian K, Liehua L, Pengyuan Z, et al. Effects of Combining Oral Hypoglycemic Agents with Short-Term Intensive Insulin Therapy on Glycemic Outcomes in Adults with Newly Diagnosed Type 2 Diabetes. Journal of Diabetes. 2026;18(1):e70187. doi:10.1111/1753-0407.70187
The 12-month diabetes remission rates were similar across all groups (p = 0.972).
78.7% of participants in the SIIT + Met + Pio group achieved HbA1c < 6.5%, significantly higher than the 59.0% in the SIIT group (adjusted p < 0.05).
Both combination groups had lower total daily insulin requirements compared to the SIIT group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin plus Sitagliptin, Metformin, SIIT for 2 weeks and Acute insulin response after SIIT, Homeostatic model assessment for insulin resistance (HOMA-IR) change, Fasting Plasma Glucose Levels Post-SIIT, and 5 more.
This study contributes evidence to
Primary intervention
Insulin plus Sitagliptin
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
8
Evidence pairs
619
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Insulin plus Sitagliptin → Acute insulin response after SIIT
Insulin plus Sitagliptin → Acute insulin response after SIIT
Insulin plus Sitagliptin → Homeostatic model assessment for insulin resistance (HOMA-IR) change
Insulin plus Sitagliptin → Homeostatic model assessment for insulin resistance (HOMA-IR) change
Metformin → Fasting Plasma Glucose Levels Post-SIIT
Metformin → Fasting Plasma Glucose Levels Post-SIIT
Metformin → Proportion of participants achieving HbA1c < 6.5%
Metformin → Proportion of participants achieving HbA1c < 6.5%
SIIT for 2 weeks → Daily bolus insulin requirements
SIIT for 2 weeks → Daily bolus insulin requirements
SIIT for 2 weeks → Total daily insulin dose
SIIT for 2 weeks → Total daily insulin dose
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Insulin Resistance, Insulin plus Sitagliptin and Acute insulin response after SIIT.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
All studies measuring Acute insulin response after SIIT
Measures Acute insulin response after SIIT as a key outcome.
All studies on Insulin plus Sitagliptin
Contributes to Insulin plus Sitagliptin evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
1 results
3 results
1 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin plus Sitagliptin appears to improve Acute insulin response after SIIT.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Acute insulin response after SIIT
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Insulin plus Sitagliptin appears to improve Homeostatic model assessment for insulin resistance (HOMA-IR) change.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Homeostatic model assessment for insulin resistance (HOMA-IR) change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Metformin appears to improve Fasting Plasma Glucose Levels Post-SIIT.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose Levels Post-SIIT
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
